Alkem Laboratories Limited has announced the resignation of its Chief Executive Officer and Key Managerial Personnel, Dr. Vikas Gupta, who will step down from his role to pursue new professional opportunities.
In a regulatory filing dated April 24, 2026, the company stated that Dr. Gupta will continue in his position until June 30, 2026, to ensure a smooth transition of responsibilities.
The resignation has been disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations. The company also noted that detailed disclosures, including the formal resignation letter, have been provided as part of the filing.
In his resignation letter, Dr. Gupta described his tenure as CEO as a “profound honour,” highlighting the progress made in strengthening Alkem’s market position, advancing its research and development pipeline, and navigating the evolving global pharmaceutical landscape. He expressed confidence in the company’s future growth and committed to supporting a seamless transition during his remaining tenure.
Dr. Gupta also acknowledged the support of the company’s board, promoter group, and employees, stating that the collective efforts have helped build a resilient and future-ready organisation.
The development marks a key leadership change for Alkem Laboratories, a major player in India’s pharmaceutical sector, and comes at a time when companies in the space are focusing on global expansion and innovation-led growth.
Further updates on leadership succession are expected in due course.
Disclaimer: This article is based on company filings and is for informational purposes only. It does not constitute investment advice.